retatrutide phase 2 nejm 2023 obesity trial results 🤔 Adults with type diabetes (T2D) and lose less weight on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today 💉 Retatrutide may be redefining

Weeks 13 through 18: 8mg weekly The jump to 8mg is where the conservative schedule provides the most benefit

Participants will need to meet whatever other requirements CMS puts in place, such as participating in lifestyle modifications

The condition results from blocked blood flow to the optic nerve and has no effective treatment, making the vision loss permanent in nearly all cases

Several factors, including age, metabolism, lifestyle, and adherence to medication, can impact the speed at which you see results

While there has been no change in law, CMS clarified that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use